NBIX - Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21 revenue of $498.8M beats by $19.77M
2023-10-31 07:07:10 ET
More on Neurocrine Biosciences
- Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
- Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
- Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts
- Neurocrine Biosciences Q3 2023 Earnings Preview
- Neurocrine says new Ingrezza version is under FDA review
For further details see:
Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21, revenue of $498.8M beats by $19.77M